IVIG, Steroids for Multisystem Inflammatory Syndrome in Children Have Varying Outcomes
November 16th 2022Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.
Read More
Novel Migraine Treatment Shows Mixed Results in Phase 3 Efficacy Trial
November 16th 2022Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.
Read More